Literature DB >> 18938746

Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.

Jean C Y Wang1.   

Abstract

Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18938746     DOI： 10.1016/j.stem.2007.10.005

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  22 in total

Review 1.  Targeting breast cancer stem cells.

Authors:  Sean P McDermott; Max S Wicha
Journal:  Mol Oncol       Date:  2010-06-17       Impact factor: 6.603

Review 2.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Authors:  Daniel A Pollyea; Jonathan A Gutman; Lia Gore; Clayton A Smith; Craig T Jordan
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

3.  Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Authors:  Timothy E Andrews; Dan Wang; Daniel A Harki
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

4.  Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling.

Authors:  Demirkan B Gürsel; Matei A Banu; Nicholas Berry; Roberta Marongiu; Jan-Karl Burkhardt; Keith Kobylarz; Michael G Kaplitt; Shahin Rafii; John A Boockvar
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

5.  NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.

Authors:  Mitchell S Cairo; Craig T Jordan; Carlo C Maley; Clifford Chao; Ari Melnick; Scott A Armstrong; Warren Shlomchik; Jeff Molldrem; Soldano Ferrone; Crystal Mackall; Laurence Zitvogel; Michael R Bishop; Sergio A Giralt; Carl H June
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-12       Impact factor: 5.742

6.  Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction.

Authors:  Demirkan B Gürsel; Robel T Beyene; Christoph Hofstetter; Jeffry P Greenfield; Mark M Souweidane; Michael Kaplitt; Margarita Arango-Lievano; Brian Howard; John A Boockvar
Journal:  J Neurooncol       Date:  2011-02-19       Impact factor: 4.130

7.  Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Authors:  Ines Herrmann; Patrick A Baeuerle; Matthias Friedrich; Alexander Murr; Susanne Filusch; Dominik Rüttinger; Mariam W Majdoub; Sherven Sharma; Peter Kufer; Tobias Raum; Markus Münz
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

8.  Self-renewal as a therapeutic target in human colorectal cancer.

Authors:  Antonija Kreso; Peter van Galen; Nicholas M Pedley; Evelyne Lima-Fernandes; Catherine Frelin; Thomas Davis; Liangxian Cao; Ramil Baiazitov; Wu Du; Nadiya Sydorenko; Young-Choon Moon; Lianne Gibson; Yadong Wang; Cherry Leung; Norman N Iscove; Cheryl H Arrowsmith; Eva Szentgyorgyi; Steven Gallinger; John E Dick; Catherine A O'Brien
Journal:  Nat Med       Date:  2013-12-01       Impact factor: 53.440

9.  Cancer stem cells: controversial or just misunderstood?

Authors:  Craig T Jordan
Journal:  Cell Stem Cell       Date:  2009-03-06       Impact factor: 24.633

10.  Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia.

Authors:  Suzanne Schubbert; Anjelica Cardenas; Harrison Chen; Consuelo Garcia; Wei Guo; James Bradner; Hong Wu
Journal:  Cancer Res       Date:  2014-10-06       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.